Support Vector Machine as a Supervised Learning for the Prioritization of Novel Potential SARS-CoV-2 Main Protease Inhibitors

Nedra Mekni, Claudia Coronnello, Thierry Langer, Maria De Rosa, Ugo Perricone

TL;DR

This paper presents a machine learning approach using Support Vector Machines (SVMs) to identify potential inhibitors of the SARS-CoV-2 main protease (Mpro), a crucial enzyme for viral replication. By training an SVM on existing Mpro inhibitor data, the researchers successfully screened millions of compounds, prioritizing a smaller set for further in-depth analysis using molecular docking and dynamics simulations.

What Problem Does This Paper Address?

The COVID-19 pandemic highlighted the urgent need for effective antiviral drugs. The SARS-CoV-2 virus relies on its main protease (Mpro) to process viral proteins essential for its replication. Therefore, Mpro is a prime target for drug development. Traditional drug discovery methods like high-throughput screening (HTS) can be time-consuming and expensive. This paper aims to accelerate the identification of novel Mpro inhibitors by leveraging machine learning to pre-screen a vast library of chemical compounds, thereby focusing experimental efforts on the most promising candidates.

Methods

The core of this study is the development and application of a Support Vector Machine (SVM) model for classifying potential Mpro inhibitors.

  1. Feature Selection: To build an effective SVM, the researchers first performed feature selection. They used a Random Forest (RF) combined with Recursive Feature Elimination (RFE) and Cross-Validation (RF-RFE-CV). This process aims to identify the most relevant molecular descriptors that correlate with Mpro inhibitory activity, reducing noise and improving model efficiency.
  2. SVM Model Training: The selected molecular descriptors were then used to train an SVM model. Hyperparameters for the SVM (kernel type, C, and gamma) were optimized using a grid search algorithm with cross-validation to achieve the best accuracy and precision.
  3. Structure-Based Virtual Screening: After training, the SVM model was applied to screen a large dataset of commercially available compounds.
  4. Docking and Molecular Dynamics: Compounds predicted as active by the SVM were further evaluated using consensus docking studies against two Mpro protein structures (PDB IDs 6WCO and 5RGW). The binding modes and interactions were analyzed. The top candidates were then subjected to molecular dynamics (MD) simulations (up to 200 ns) to assess the stability of their interactions with the Mpro protein.

Datasets

  • PostEra COVID-19 Moonshot dataset: This dataset, containing approximately 719 compounds with reported fluorescence assay activity (IC50 values) against SARS-CoV-2 Mpro, was used for training and testing the SVM model.
  • Commercial Libraries (MolPort, Asinex, and ChEMBL): Approximately 2 million compounds from these libraries were screened using the trained SVM model.

Key Insights and Ideas

  • Machine Learning as a Powerful Filter: The study demonstrates that an SVM, trained on a relatively modest dataset, can effectively filter a massive chemical space to identify promising drug candidates. This significantly reduces the experimental burden.
  • Importance of Specific Molecular Descriptors: The feature selection process highlighted that descriptors related to charge distribution, polarizability, and electronegativity are crucial for predicting Mpro inhibitory activity. This suggests that these electronic properties play a key role in how molecules interact with the Mpro active site.
  • Conserved Residue Glu166 as a Key Interaction Point: Molecular dynamics simulations revealed that the residue Glu166 consistently forms stable hydrogen bonds with the identified potential inhibitors. This residue is known to be conserved across coronaviruses and is critical for Mpro dimerization and catalytic activity, making it a highly valuable target.
  • Sulfonamide Moiety as a Promising Feature: The sulfonamide functional group appeared frequently in the top-ranked compounds, suggesting its potential utility in designing novel Mpro inhibitors, aligning with existing literature on sulfonamide-based antivirals.

Key Results

  • The trained SVM model achieved an accuracy of 0.88 on the test set.
  • The SVM model successfully classified 200 novel chemo-types as potentially active from a pool of 2 million compounds.
  • Consensus docking and molecular dynamics simulations identified five promising compounds with favorable binding modes and stable interactions with Mpro.
  • These top compounds exhibited interactions with key Mpro residues, including Glu166, His41, and Gly143, consistent with known inhibitor binding patterns.

Limitations and Future Work

  • Limited Training Data Size: The authors acknowledge that the SVM model was built using a "limited number of compounds." While it proved effective, a larger and more diverse training dataset could potentially lead to an even more robust model.
  • In Silico Prediction: The identified compounds are potential inhibitors based on computational predictions. Experimental validation through biological assays is the crucial next step to confirm their efficacy and safety.
  • Future Work: The paper states that the compounds with the most interesting binding poses will be biologically assayed and validated against the viral protease. This experimental validation is essential to confirm the computational findings and advance these candidates towards potential therapeutic use.

Summary updated

Abstract

In the last year, the COVID-19 pandemic has highly affected the lifestyle of the world population, encouraging the scientific community towards a great effort on studying the infection molecular mechanisms. Several vaccine formulations are nowadays available and helping to reach immunity. Nevertheless, there is a growing interest towards the development of novel anti-covid drugs. In this scenario, the main protease (Mpro) represents an appealing target, being the enzyme responsible for the cleavage of polypeptides during the viral genome transcription. With the aim of sharing new insights for the design of novel Mpro inhibitors, our research group developed a machine learning approach using the support vector machine (SVM) classification. Starting from a dataset of two million commercially available compounds, the model was able to classify two hundred novel chemo-types as potentially active against the viral protease. The compounds labelled as actives by SVM were next evaluated through consensus docking studies on two PDB structures and their binding mode was compared to well-known protease inhibitors. The best five compounds selected by consensus docking were then submitted to molecular dynamics to deepen binding interactions stability. Of note, the compounds selected via SVM retrieved all the most important interactions known in the literature.
BibTeX
@article{mekni2025support,
  author = {Nedra Mekni and Claudia Coronnello and Thierry Langer and Maria De Rosa and Ugo Perricone},
  title = {{Support Vector Machine as a Supervised Learning for the Prioritization of Novel Potential SARS-CoV-2 Main Protease Inhibitors}},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  url = {https://openreview.net/forum?id=OCbF3K7Lt5},
}
Figure